BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will present at the following investor conferences:
TD Cowen's 6th Annual Oncology Innovation Summit: Insights from ASCO & EHA
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 1:00 p.m. ET
Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 4, 2025
Time: 4:20 p.m. ET
Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, June 10, 2025
Time: 4:00 p.m. ET
The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 90 days following the conclusion of the live event.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
| Last Trade: | US$16.77 |
| Daily Change: | -0.16 -0.95 |
| Daily Volume: | 102,639 |
| Market Cap: | US$819.380M |
May 14, 2025 March 13, 2025 February 25, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
